U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06927232) titled 'AZA+Lus VS AZA Monotherapy in HR-MDS' on April 01.
Brief Summary: This study is a randomized, prospective, single-center, open-label cohort study involving untreated HR-MDS patients. The patients were divided randomized into AZA+Lus cohort and AZA monotherapy cohort.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Higher-risk Myelodysplastic Syndrome
Intervention:
DRUG: Azacitidine (AZA)
Azacitidine 75mg/m/ day *5 days, 28 days for 1 course
DRUG: Luspatercept
Luspatercept 1.0 mg/kg subcutaneously every 3 weeks, adjusted according to hemoglobin, up to 1.75mg/kg. If hemoglobin >=120g/L, luspatercept can b...